Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.
EP. 1: Evolving Paradigms in the Detection and Treatment of Prostate Cancer
Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.
EP. 2: Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression
Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.
EP. 3: Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes
Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.
EP. 4: Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs
Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer